EyePoint Pharmaceuticals, Inc. (EYPT) vs Palisade Bio, Inc. (PALI)
A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and Palisade Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EYPT
EyePoint Pharmaceuticals, Inc.
$3.19HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
PALI
Palisade Bio, Inc.
$1.51HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — EYPT vs PALI
growth of $100 · dividends reinvested · last 10yEYPT -89.5% (-20.2%/yr)PALI -100.0% (-71.2%/yr)EYPT compounded faster over this window
Log scale — wide-divergence pair
EYPT PALI
EYPT vs PALI: by the numbers
- •EYPT is the larger company ($267M vs $261M market cap).
- •Both run net losses; PALI's is the smaller (-6388.20% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | EYPT | PALI |
|---|---|---|
| P/S ratio | 95.75 | 522.47 |
| P/B ratio | 1.60 | 2.15 |
Profitability
| Metric | EYPT | PALI |
|---|---|---|
| Gross margin | 93.41% | 0.00% |
| Operating margin | -775.98% | 0.00% |
| Net margin | -10994.73% | -6388.20% |
| ROE | -184.27% | -26.24% |
| ROIC | -170.19% | -28.96% |
Growth (annualized)
| Metric | EYPT | PALI |
|---|---|---|
| Revenue CAGR (5Y) | -41.05% | N/A |
| Total return CAGR (5Y) | -21.68% | -76.02% |
Frequently asked
- How have EYPT and PALI total returns compared?
- Over the past 10 years, EYPT delivered -20.02% and PALI delivered -71.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.